Entero Therapeutics Announces Material Agreement, Officer Changes
Ticker: GRDX · Form: 8-K · Filed: Mar 25, 2025 · CIK: 1604191
| Field | Detail |
|---|---|
| Company | Entero Therapeutics, Inc. (GRDX) |
| Form Type | 8-K |
| Filed Date | Mar 25, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, management-change, corporate-action
TL;DR
Entero Therapeutics (formerly First Wave BioPharma) inked a material deal and shuffled execs on 3/24.
AI Summary
Entero Therapeutics, Inc. announced on March 24, 2025, a material definitive agreement and changes in its board and officer composition. The company also disclosed financial statements and exhibits. This filing follows a period of name changes, previously being known as First Wave BioPharma, Inc., AzurRx BioPharma, Inc., and BioPharma d'Azur, Inc.
Why It Matters
This 8-K filing signals significant corporate activity, including a new material agreement and changes in leadership, which could impact the company's strategic direction and operational execution.
Risk Assessment
Risk Level: medium — The filing indicates significant corporate actions like a material definitive agreement and changes in officers, which can introduce uncertainty and potential risks.
Key Players & Entities
- Entero Therapeutics, Inc. (company) — Registrant
- First Wave BioPharma, Inc. (company) — Former Company Name
- AzurRx BioPharma, Inc. (company) — Former Company Name
- BioPharma d'Azur, Inc. (company) — Former Company Name
- March 24, 2025 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Entero Therapeutics?
The filing does not specify the details of the material definitive agreement, only that one was entered into on or before March 24, 2025.
What specific changes occurred regarding directors or officers?
The filing indicates changes in directors or certain officers, election of directors, and appointment of certain officers, as well as compensatory arrangements, but does not provide specific names or details within this summary.
When was Entero Therapeutics previously known as First Wave BioPharma, Inc.?
The company's name was changed from First Wave BioPharma, Inc. on September 21, 2021.
What is the primary business of Entero Therapeutics?
Entero Therapeutics, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
What is the filing date and the earliest event date for this 8-K?
The filing date is March 25, 2025, and the date of the earliest event reported is March 24, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 25, 2025 regarding Entero Therapeutics, Inc. (GRDX).